A guidance regarding potential interactions with concomitant medications is provided
Concomitant medications with another AR antagonist that would increase the risk of seizure (e.g., theophylline, aminophylline).
EXCLUDED THERAPIES AND MEDICATIONS, PREVIOUS AND CONCOMITANT
Concomitant Medications:
There are currently no known concomitant medications that must be discontinued prior to administration of registration on study and for the duration of sEphB-HSA
Concomitant medications:
Concomitant medications, if taken within the last  days
Concomitant medications:
Any condition which could jeopardise the safety of the patient and his/her compliance in the study Excluded therapies and medications, previous and concomitant:
Concomitant medications: patients receiving anticoagulation should be on stable dose  weeks prior to registration
Requirement for concomitant medications that strongly induce or inhibit CYPA/
Concomitant medications causing prolonged QT which cannot be discontinued or changed to a different medication prior to initiating study
Patients requiring concomitant medications that are not able to be switched to a reasonable alternative
Concomitant therapy medications that include corticosteroids (except as indicated in inclusion criteria)
Participants may not be receiving any other investigational agents for  days prior to baseline evaluation and during the study intervention (which will be captured on the Concomitant Medications CRFs)
Concomitant use of medications that may alter pharmacokinetics of enzalutamide
EXCLUDED THERAPIES AND MEDICATIONS, PREVIOUS AND CONCOMITANT
Excluded therapies and medications, previous and concomitant:
Patients who are receiving concomitant D-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registration
Concomitant Medication and Treatment: \r\n* All allowed medications or treatments should be kept to a minimum and recorded; all questions regarding concomitant medications should be referred to the Investigator
Concomitant medications should be avoided (when possible) while on study
Has a condition that requires the concomitant use of any of the protocol-excluded medications, supplements, or food products during the course of the study .
Participants who take medications that are not recommended for concomitant use with their current antiretroviral regimen
Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM
Concomitant medications that are known inducers of CYP.
Concomitant use of medications that may alter pharmacokinetics of abiraterone or apalutamide
No exclusion criteria relating to concomitant medications
Concomitant use of medications known to induce a disulfiram-like reaction to alcohol
There will be no exclusion criteria relating to concomitant medications
Concomitant medications:
Patients required to be on any of the concomitant medications are excluded